Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Rattus norvegicus, rat |
| Cell Line Description | AY-27 is a rat transitional cell carcinoma (TCC) cell line derived from a primary bladder tumor induced by the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) in a Fischer 344 (F344) rat. As a highly characterized and widely utilized syngeneic model, it occupies a prominent position in the field of bladder cancer research. AY-27 cells exhibit an epithelial-like morphology and are distinguished by their highly aggressive growth characteristics and consistent success rate upon transplantation. This cell line is regarded as the "gold standard" for establishing orthotopic bladder cancer models in immunocompetent rats, enabling researchers to comprehensively investigate intravesical therapeutic modalities (such as Bacillus Calmette-Guérin [BCG], Mitomycin C, or photodynamic therapy), tumor-host immune interactions, and the mechanisms of local tumor invasion within the urinary tract. |
| Tissue | Urinary Bladder |
| Disease | Transitional Cell Carcinoma (TCC); Bladder Cancer |
| Morphology | Epithelial-like |
| Gender | Not specified (derived from F344 rat) |
| Age | Adult |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Bladder cancer pathogenesis and syngeneic rat model research 2. Evaluation of intravesical chemotherapy and immunotherapy (e.g., BCG) 3. Study of photodynamic therapy (PDT) and laser-based treatments 4. Investigation of tumor cell adhesion and orthotopic implantation techniques 5. Preclinical screening for novel anti-urothelial cancer drugs |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes, highly tumorigenic in syngeneic Fischer 344 (F344) rats |
| Growth Kinetics | Rapid doubling time in vitro; reliable orthotopic tumor take rate |
| Phenotype | Maintains high-grade malignant features of urothelial carcinoma |
| Antigenicity | Strong immunogenicity in syngeneic hosts; suitable for vaccine studies |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically requiring 3 to 7 minutes). 4. Add complete growth medium to neutralize the trypsin, and gently pipette to create a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A split ratio of 1:3 to 1:8 is recommended |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR00728 | Luciferase Reporter Cell Line - AY-27 | Inquiry |
Copyright © Creative Biogene. All rights reserved.